Scholarlink

<p>Lung cancer remains the leading cause of cancer-related mortality worldwide, accounting for approximately 2.2&#xa0;million new cases and 1.8&#xa0;million deaths annually. Non–small cell lung cancer (NSCLC) constitutes nearly 85% of all cases, underscoring its substantial global burden. This study reports the development of hyaluronic acid–bovine serum albumin (HA–BSA)-coated nanostructured lipid carriers (NLCs) for targeted combinational delivery of fisetin and flavokawain A in NSCLC using a Quality-by-Design (QbD) approach. The optimized formulation demonstrated a particle size of ~ 115&#xa0;nm with a low polydispersity index (&lt; 0.3) and high zeta potential (~–40.8 mV), indicating excellent colloidal stability. Drug entrapment efficiency reached ~ 85.5–89.5%, while cumulative drug release exhibited a sustained profile (~ 90–93.8% over 9&#xa0;h). Solid-state characterization confirmed reduced crystallinity and successful encapsulation. Stability studies showed negligible changes in particle size (162.5 to 165.1&#xa0;nm) and drug content (&gt; 98%) under refrigerated conditions over 6 months. In vitro cytotoxicity studies revealed significantly enhanced anticancer activity, with the formulation achieving up to ~ 70.32% inhibition of A549 cells compared to lower activity of free drug. Statistical optimization confirmed model significance (<i>p</i> = 0.0385) and good reproducibility (CV &lt; 3%). Overall, the developed HA–BSA-coated NLCs offer a robust, stable, and efficient nanoplatform for improved flavonoid delivery in NSCLC therapy.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hyaluronic acid- bovine serum albumin coated nanostructured lipid carriers for targeted combinational delivery of fisetin and flavokawain A in non–small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月10日

查看全文
  • Anjum N. Hasnain,
  • Darshan R Telange,
  • Devesh U Kapoor

摘要

Lung cancer remains the leading cause of cancer-related mortality worldwide, accounting for approximately 2.2 million new cases and 1.8 million deaths annually. Non–small cell lung cancer (NSCLC) constitutes nearly 85% of all cases, underscoring its substantial global burden. This study reports the development of hyaluronic acid–bovine serum albumin (HA–BSA)-coated nanostructured lipid carriers (NLCs) for targeted combinational delivery of fisetin and flavokawain A in NSCLC using a Quality-by-Design (QbD) approach. The optimized formulation demonstrated a particle size of ~ 115 nm with a low polydispersity index (< 0.3) and high zeta potential (~–40.8 mV), indicating excellent colloidal stability. Drug entrapment efficiency reached ~ 85.5–89.5%, while cumulative drug release exhibited a sustained profile (~ 90–93.8% over 9 h). Solid-state characterization confirmed reduced crystallinity and successful encapsulation. Stability studies showed negligible changes in particle size (162.5 to 165.1 nm) and drug content (> 98%) under refrigerated conditions over 6 months. In vitro cytotoxicity studies revealed significantly enhanced anticancer activity, with the formulation achieving up to ~ 70.32% inhibition of A549 cells compared to lower activity of free drug. Statistical optimization confirmed model significance (p = 0.0385) and good reproducibility (CV < 3%). Overall, the developed HA–BSA-coated NLCs offer a robust, stable, and efficient nanoplatform for improved flavonoid delivery in NSCLC therapy.

Graphical abstract